Randomized trial demonstrates enhanced antipsychotic efficacy in a rat model of schizophrenia, suggesting a novel delivery approach.
Key Points
This research aims to develop a novel delivery system for aripiprazole that improves its effectiveness for treating schizophrenia by enhancing brain exposure.
Developed intranasal chitosan nanoparticles modified with sodium dodecyl sulfate using ionic gelation.
Optimized formulation parameters through a Box–Behnken design for particle characteristics.
Conducted pharmacokinetic and pharmacodynamic testing in ketamine-induced psychosis rat models.
Enhanced aripiprazole bioavailability and brain uptake observed following intranasal administration of optimized nanoparticles compared to other routes.
Improved antipsychotic efficacy noted in rat models with significant neurochemical restoration (dopamine and GABA).
Histopathological findings confirmed structural improvements in hippocampal and cortical regions.